(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said. Reuters could not immediately confirm the FT report. (Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Researchers have used smartwatches to catch cognition in real time and found older adults’ self-ratings…
First the workout plan, then the supplements, then the sleep index: At some point, you…
Washington (dpa) - New research suggests that a respectful and formal approach is the most effective…
London (dpa) - This year’s El Niño is set to be the strongest "in living…
Berlin (dpa) - With colorectal cancer case numbers rising among younger and middle-aged adults, doctors…
Washington (dpa) - Makers of personal and domestic hygiene products are not disclosing their use of…